HE Ruyi, Eminent Chairman of PhIRDA International Regulatory Science Specialty Committee,
CEO of Global Health Innovation Institute
09:00 - 09:10
致辞
Remarks
茹涛, 上海国投先导生物医药母基金董事总经理
RU Tao, MD, Healthcare Fund, SSCILF
09:10 - 10:50
主题一：医疗健康产业趋势及“十五五”规划展望
Topic 1：Trends in the healthcare industry and outlook for the 15th Five-Year Plan
09:10 - 09:40
主题报告1
Keynote Speech 1
AI赋能，多元支付支持创新药械发展的创新实践
Innovative Practice of AI Empowerment and Diversified Payment Support for the Development of Innovative Medical Devices
劳远至, 先声药业香港协同创新中心总经理
LAO Yuanzhi, Senior Director, Hong Kong Collaborative Innovation Center Simcere Pharmaceutical Group
09:40 - 10:10
主题报告2
Keynote Speech 2
攘外必先“安内”，医药改革进入密集期
To “Stabilize the Internal”before “Tackling the External”: The Pharmaceutical Reform Has Entered an Intensive Phase
余刚, 华领医药法规事务副总裁
YU Gang, VP, Regulatory Affairs of Hua Medicine
10:10 - 10:50
讨论1
Panel 1
医疗健康产业发展及投资机会研判
Analysis of the Development and Investment Opportunities in the Medical and Health Industry
主持人 Moderator
简依雯, 香港科技园公司创新发展总监
Pheona KAN, Director of New Ventures, Hong Kong Science and Technology Parks Corporation
讨论嘉宾： Panelist:
康韦, 粤港澳大湾区医药创新联合会创始人
KANG Wei, Founder & Chief Advisor of GBAAPI
刘江, 香港大学外科学系研究助理教授，迈康因科技研发负责人
LIU Jiang, Research Assistant Professor of Department of Surgery of The University of Hong Kong, Research Lead of Oncoimmunostics Ltd.
马骏一, 海邻科技大湾区总经理
MA Junyi, General Manager of GBA, HILINK
宇文镐, 博士，斯丹姆医药全球注册高级副总裁兼首席商务官
Howard YUWEN, SVP & CBO at SDM Bioservices
吴静, 中国疾病预防控制中心慢性非传染性疾病预防控制中心主任
WU Jing, Director, National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention
余刚, 华领医药法规事务副总裁
YU Gang, VP, Regulatory Affairs of Hua Medicine
10:50 - 12:30
主题二：企业境内上市审核及发行动态
Topic 2：Updates on Domestic IPO Review and Issuance Processes for Enterprises
10:50 - 11:20
主题报告 3
Keynote Speech 3
全面深化资本市场改革开放推动科技创新和产业创新融合发展
Comprehensively Deepening Capital Market Reform and Opening Up to Drive the Synergistic Development of Technological and Industrial Innovation
11:20 - 11:50
主题报告 4
Keynote Speech 4
近期A股IPO市场环境分析
Analysis of the Recent A-Shares IPO Market Environment
毕艳, 南京大学医学院附属鼓楼医院院长兼临床医学研究院院长
BI Yan, President, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School; Director, Institute of Clinical Medicine
11:50 - 12:30
讨论2
Panel 2
科创板第五套标准重启后，对尚未盈利的创新药企业意味着哪些机遇与挑战
Opportunities and Challenges for Pre-Revenue Innovative Drug Companies Under the Fifth Set of Standards for the STAR Market
主持人 Moderator
王博, 辉瑞（北京）研究开发有限公司内科领域负责人
WANG Bo, Senior Director, Senior Category Development Lead at Pfizer China
讨论嘉宾： Panelist:
宋文鑫, 上海民为生物技术有限公司首席科学家、副总经理
SONG Wenxin, Chief Scientist and Deputy General Manager, Shanghai Minwei Biotechnology Co., Ltd.
张纪阳, 复旦大学附属中山医院大数据人工智能中心主任
ZHANG Jiyang, Director of the Big Data and Artificial Intelligence Center, Zhongshan Hospital, Fudan University
毕艳, 南京大学医学院附属鼓楼医院院长兼临床医学研究院院长
BI Yan, President, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School; Director, Institute of Clinical Medicine
卢海, 杭州中美华东制药有限公司研发中心医学执行总监
LU Hai, Executive Medical Director, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
14:00 - 16:20
主题三：企业境外上市审核发行动态
Topic 3：Updates on Overseas IPO Review and Issuance Processes for Enterprises
14:00 - 14:10
致辞
Remarks
Ramy Younes, 勃林格殷格翰副总裁、全球心肾代谢领域临床开发负责人
Ramy Younes, Corporate Vice President Global Head of Clinical Development CRM at Boehringer Ingelheim
14:10 - 14:40
主题报告5
Keynote Speech 5
医疗健康行业港股资本市场动态概览
Overview of Developments in the Hong Kong Stock Capital Market for the Healthcare Industry
张怡, 华领医药执行董事、全球药品开发部高级副总裁、首席医学官
ZHANG Yi, Executive Director, Senior Vice President of Pharmaceutical Development, and Chief Medical Officer, Hua Medicine
14:40 - 15:10
主题报告6
Keynote Speech 6
境外上市中国证监会备案审核要点解析
Instrumental Tactics on CSRC Filing for Overseas IPO
丁巍, 杏泽资本合伙人
DING Wei, Partner, Apricot Capital
15:10 - 15:40
主题报告7
Keynote Speech 7
企业香港上市财务关注重点
Key Financial Focus of Listing on HKEX
张晓青, 翰森制药集团首席医学官
ZHANG Xiaoqing, Chief Medical Officer, Hansoh Pharmaceutical Group Co., Ltd.
15:40 - 16:20
讨论3
Panel 3
药企寻求海外上市的主要考量，以及医药公司上市后的业务拓展机会
Key Considerations for Pharmaceutical Companies Seeking Overseas Listings and Post-IPO Business Expansion Opportunities
主持人 Moderator
曲伸, 同济大学医学院肥胖症研究所所长，同济大学附属上海十院肥胖症管理中心主任
QU Shen, Director, Institute of Obesity, Tongji University School of Medicine; Director, Obesity and Metabolism Management Center, Shanghai Tenth People's Hospital, Tongji University
讨论嘉宾： Panelist:
Brendan SHAW, Principal of Shawview Consulting
Brendan SHAW, Principal of Shawview Consulting
田志刚, 中国工程院院士，欧洲科学院院士，中国科学技术大学学术委员会副主任、免疫学研究所所长
TIAN Zhigang, Academician of the Chinese Academy of Engineering; Member of Academia Europaea; Deputy Director of the Academic Committee, University of Science and Technology of China; Director of the Institute of Immunology
白丽, 中国科学技术大学生命科学与医学部教授
BAI Li, Professor, Division of Life Sciences and Medicine, University of Science and Technology of China
刘守邦, 南京市创新投资集团总经理助理
LIU Shoubang, Assistant General Manager, Nanjing Innovation Capital Group
丁巍, 杏泽资本合伙人
DING Wei, Partner, Apricot Capital
李海军, 广东众生睿创生物科技有限公司总裁
LI Haijun, President, Guangdong Zhongsheng Ruichuang Biological Technology Co., Ltd.
会议咨询